Avacopan is possibly associated with the improvement of ANCA-associated vasculitis activity without decreasing ANCA titres: a four-case series.

The article discusses the results of a study on the effectiveness of C5a receptor antagonist avacopan in the management of patients with antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Topics mentioned include a description of the medical history of patients with AAV, the changes in ANCA titres after the administration of avacopan, and the mechanism of action of avacopan.